Mayo Clinic Laboratory and pathology research roundup: June 7

By Meghann Southwick • June 7, 2022

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Nuclear GSK-3β and oncogenic KRas lead to the retention of pancreatic ductal progenitor cells phenotypically similar to those seen in IPMN.

Glycogen synthase kinase-3β (GSK-3β) is a downstream target of oncogenic KRas and can accumulate in the nucleus in pancreatic ductal adenocarcinoma (PDA). To determine the interplay between oncogenic KRas and nuclear GSK-3β in PDA development, we generated Lox-STOP-Lox (LSL) nuclear-targeted GSK-3β animals and crossed them with LSL-KRas^G12D mice under the control of the Pdx1-cre transgene-referred to as KNGC. Altogether, these data identify nGSK-3β and KRas^G12D as an important signaling node promoting the retention of pancreatic ductal progenitor cells.

Read more.

Published to PubMed This Week

• Performance of plasma phosphorylated tau 181 and 217 in the community.
  Nature medicine
• Spectrum of sublytic astrocytopathy in neuromyelitis optica.
  Brain: a journal of neurology
• Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure.
  Circulation
• IL-13Rα2 status predicts GB-13 (IL13.E13K-PE4E) efficacy in high-grade glioma.
  Pharmaceutics
• Artificial intelligence enhances diagnostic flow cytometry workflow in the detection of minimal residual disease of chronic lymphocytic leukemia.
  Cancers
• Deep neural network for cardiac magnetic resonance image segmentation.
  Journal of imaging
• Smoldering giant cell arteritis in a coronary artery.
  Rheumatology

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.